HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Reviva Pharmaceuticals in a research report issued on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($1.00) for the year, up from their prior estimate of ($1.04). HC Wainwright currently has a "Buy" rating and a $11.00 price target on the stock. The consensus estimate for Reviva Pharmaceuticals' current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals' Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.82) EPS.

A number of other research firms also recently issued reports on RVPH. Maxim Group upgraded shares of Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price objective for the company in a report on Friday, January 10th. D. Boral Capital restated a "buy" rating and set a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday. Roth Capital upgraded Reviva Pharmaceuticals to a "strong-buy" rating in a research note on Friday, January 10th. Finally, Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research report on Friday, January 10th. They issued a "buy" rating and a $7.00 target price for the company. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Reviva Pharmaceuticals presently has an average rating of "Buy" and a consensus target price of $11.40.

Reviva Pharmaceuticals Price Performance

Shares of Reviva Pharmaceuticals stock traded up $0.02 during trading hours on Friday, hitting $1.91. 1,044,266 shares of the company's stock traded hands, compared to its average volume of 2,718,291. The company has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $1.33. The stock has a market capitalization of $63.87 million, a price-to-earnings ratio of -1.72 and a beta of -0.12. Reviva Pharmaceuticals has a 12-month low of $0.60 and a 12-month high of $4.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of RVPH. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 17.9% during the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company's stock valued at $401,000 after buying an additional 42,376 shares during the period. EMC Capital Management increased its holdings in Reviva Pharmaceuticals by 142.0% during the 4th quarter. EMC Capital Management now owns 44,535 shares of the company's stock worth $81,000 after acquiring an additional 26,134 shares during the period. Finally, Drive Wealth Management LLC purchased a new stake in Reviva Pharmaceuticals in the 4th quarter worth approximately $36,000. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.